Sector News

Abbott puts one-third of its $6B Mylan stake on the block

March 31, 2015
Life sciences
Abbott Laboratories is selling off one-third of its stake in Mylan, a few weeks after Mylan wrapped up its $5.3 billion stock swap for a portfolio of Abbott’s specialty and branded drugs.
 
Abbott will sell 35 million of the approximately 110 million shares it acquired in that stock swap, about 32% of its stake. The original deal, announced last July, handed Pittsburgh-based generics specialist Mylan a sizable chunk of Abbott’s drug business in developed countries outside the U.S. The portfolio of 100 branded and generic meds brought in $2 billion in 2013 sales, Mylan says.
 
In addition to those drug rights, Mylan gained Abbott’s commercial infrastructure in those markets, which could help it expand sales for its EpiPen injection for anaphylactic shock and launch copies of Teva Pharmaceutical’s multiple sclerosis powerhouse Copaxone and GlaxoSmithKline’s respiratory behemoth Advair, CEO Heather Bresch said at the time of the deal.
 
As part of the stock swap, Mylan and Abbott engineered a tax inversion. The deal created a Netherlands-based operation that would become Mylan’s headquarters for tax purposes. But the two companies had to tweak the terms of the deal after the U.S. Treasury cracked down on companies using M&A to move to tax-friendly countries.
 
The Abbott buy also marked a change of pace for Mylan, which had focused much of its prior dealmaking on emerging markets. The company last year joined forces with Gilead Sciences to roll out HIV drugs in India, launched a biosimilar version of Roche’s blockbuster cancer med Herceptin in that market, and snatched up some Indian plants and development facilities.
 
Mylan in 2013 inked a $1.6 billion deal for India-based Agila Specialties, the injectables unit of Strides Arcolab, picking up a global commercial and manufacturing network to expand the reach for its products.
 
By Emily Wasserman
 

Related News

February 28, 2021

UCB taps Microsoft to accelerate drug discovery, clinical trials

Life sciences

The deal will see Microsoft use its capabilities in computational services, cloud computing and artificial intelligence to support drug discovery and development at UCB.

February 28, 2021

GSK to close two UK antibiotics manufacturing sites

Life sciences

The planned closures come as GSK has agreed to sell its cephalosporins antibiotics business to Sandoz, a division of Swiss pharma firm Novartis, for as much as US$500m.

February 28, 2021

Colorcon launches TiO2-free supplement coating

Life sciences

“The launch of these new formulations provides the nutritional market with much-needed alternative coating systems that address clean label consumer preferences and are easy to implement,” says Kelly Boyer, vice president film coatings at Colorcon.

Send this to a friend